Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Science and Society
  • Published:

Engaging biotechnology companies in the development of innovative solutions for diseases of poverty

Nature Reviews Drug Discovery volume 3, pages 171–176 (2004)Cite this article

Abstract

Global policy interventions are required to ensure that the scientific and technological innovations that biotechnology companies are advancing are applied to the health needs of people in the developing world. We present an overview of the present role of biotechs in 'diseases of poverty' R&D, and outline ways to facilitate higher levels of involvement in the future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. World Health Organization. The World Health Report 2002. Reducing Risk, Promoting Healthy Life (WHO, Geneva, 2002).

  2. Barley, S. R., Freeman, J. & Hybels, R. C. in. Networks and Organisations: Structure, Form and Action Ch. 12 (eds Nohria, N. & Eccles, R.) 311–347 (Harvard Business School Press, Watertown, 1992).

    Google Scholar 

  3. Powell, W. W., Koput, K. W. & Smith-Doerr, L. Interorganisational collaboration and the locus of innovation: networks of learning in biotechnology. Adm. Sci. Q. 41, 116–145 (1996).

    Article  Google Scholar 

  4. Ashton, G., Kettler, H., Saunders, E. & McAuslane, J. External Collaboration and Licensing in Pharmaceutical R&D (CMR International, London, 2001).

    Google Scholar 

  5. Daar, A. S. et al. Top ten biotechnologies for improving health in developing countries. Nature Genet. 32, 229–232 (2002).

    Article  CAS  PubMed  Google Scholar 

  6. Gardner, M. J. et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498–511 (2002).

    Article  CAS  PubMed  Google Scholar 

  7. Casper, S. & Kettler, H. The Road to Sustainability in the UK and German Biotechnology Industries (Office of Health Economics, London, 2000).

    Google Scholar 

  8. West, J. The mystery of innovation: aligning the triangle of technology, institutions and organisation. Aust. J. Manage. 26, 21–45 (2001).

    Article  Google Scholar 

  9. Kettler, H. & White, K. Valuing Industry Contributions to Public Private Partnerships for Health Product Development (Initiative on Public Private Partnerships, 2003).

    Google Scholar 

  10. Marjanovic, S. The Role of Biotechnology Firms in the 'Global Health Challenge': Investigating the Potential for Smaller Biotech Contributions to 'Remedying' Neglected Diseases of the Developing World. Unpublished thesis, Cambridge Univ. (2002).

    Google Scholar 

  11. Milne, C., Kaitin, K. & Ronchi, E. Orphan Drug Laws in Europe and the US: Incentives for the Research and Development of Medicines for the Diseases of Poverty (CMH Working Paper Series, Paper No. WG2: 9, 2001).

    Google Scholar 

  12. Kettler, H. & Towse, A. Public–Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty (Office of Health Economics, London, 2002).

    Google Scholar 

  13. Nwaka, S. & Ridley, R. Virtual drug discovery and development for neglected diseases through public–private partnerships. Nature Rev. Drug Discov. 2, 919–928 (2003).

    Article  CAS  Google Scholar 

  14. Kettler, H. Biotechnology for Global Health: An Options and Feasibility Study. Final version prepared for the Rockefeller Foundation (2002).

    Google Scholar 

  15. Kremer, M. in Innovation Policy and the Economy (eds Jaffe, A. B., Lerner, J. & Stein, S.) (2001).

    Google Scholar 

  16. WHO/IFPMA Roundtable: Drug Development Working Group Priority Infectious Diseases Requiring Additional R&D Draft (2001).

  17. Grabowski, H. Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act (Duke Univ., Durham, 2003).

    Google Scholar 

  18. Glennerster, R. & Kremer, M. The purchase precommitment as a supplement to patents and government-funded research: a better way to spur medical research and development. Regulation 23, 34–39 (2001).

    Google Scholar 

  19. Kettler, H. E. Narrowing the Gap Between the Provision and Need for Medicines in Developing Countries (Office of Health Economics, London, 2000).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Health Initiatives, Bill and Melinda Gates Foundation, PO Box 23350, Seattle, 98102, Washington, USA

    Hannah E. Kettler

  2. Judge Institute of Management Studies, University of Cambridge, Trumpington Street, Cambridge, CB2 1AG, UK

    Sonja Marjanovic

Authors
  1. Hannah E. Kettler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonja Marjanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Bill and Melinda Gates Foundation

Biotechnology Industry Organization

Drugs for Neglected Diseases Initiative

Global Alliance for TB Drug Development

Institute for One World Health

International AIDS Vaccine Initiative

Malaria Vaccine Initiative

Medicines for Malaria Venture

Office of Health Economics

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kettler, H., Marjanovic, S. Engaging biotechnology companies in the development of innovative solutions for diseases of poverty. Nat Rev Drug Discov 3, 171–176 (2004). https://doi.org/10.1038/nrd1308

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1308

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing